Tools of Biological Warfare

Research Journal of Microbiology

Volumn 6, Issue 3, 2011, Pages 193-245

  Al Agamy, Mohamed H M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649339917     PISSN: 18164935     EISSN: None     Source Type: Journal    
DOI: 10.3923/jm.2011.193.245     Document Type: Article

References (247)

1. Aken, J.V. and E. Hammond, 2003. Genetic engineering and biological weapons. EMBO Rep., 4: S57-S6O.
2. Alibek, K. and S. Handelman, 1999. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World, Told From the Inside by the Man Who Ran It. Random House Inc., New York.
3. Arnon, S.S., R. Schechter, T.V. Inglesby, A. Donald and M.D. Henderson et al., 2001. Botulinum toxin as a biological weapon: Medical and public health management. JAMA, 285: 1059-1070.
4. Azad, A. and S. Radulovic, 2003. Pathogenic rickettsiae as bioterrorism agents. Ann. N. Y. Acad. Sci., 990: 734-738.
5. Baillie, L. and T.D. Read, 2001. Bacillus anthracis: Abug with attitude. Curr. Opin. Microbiol., 4: 78-81.
6. Bandouchova, H., J. Sedlackova, M. Hubalek, M. Pohanka and L. Peckova et al., 2009. Susceptibility of selected murine and microtine species to infection by a wild strain of Francisella tularensis subsp. holoarctica. Vet. Med., 54: 64-74.
7. Bartlett, J.G., Jr. T.V. Inglesby and L. Borio, 2002. Management of Anthrax. Clin. Infec. Dis., 35: 851-858.
8. Bartlett, J., L. Borio, L. Radonovich, J.S. Mair and T. O'Toole et al., 2003. Smallpox vaccination in 2003: Key information for clinicians. Clin. Infect. Dis., 36: 883-902.
9. Bazhutin, N.B., E.F. Belanov, V.A. Spiridonov, A.V. Yoitenko and N.A. Krivenchuk et al., 1992. The effect of the meth-ods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Yopr. Virusol., 37: 153-156.
10. Bermudez, J.S, 2001. The Armed Forces of North Korea. IB Tauris Publisher, London, England.
11. Beyer, W., S. Pocivalsek and R. Bohm, 1999. Polymerase chain reaction-ELISA to detect Bacillus anthracis from soil samples: Limitations of present published primers. J. Applied Microbiol., 87: 229-236.
12. Bhalla, D.K. and D.B. Warheit, 2004. Biological agents with potential for misuse: A historical perspective and defensive meseaures. Toxicol. Applied Pharmacol., 199: 71-84.
13. Bianucci, R., L. Rahalison, E.R. Massa, A. Peluso, E. Ferroglio and M. Signoli, 2008. Technical note: A rapid diagnostic test detects plague in ancient human remains: An example of the interaction between archeological and biological approaches (southeastern France, 16th-18th centuries). Am. J. Phys. Anthropol., 136: 361-367.
14. Bigalke, H. and A. Rummel, 2005. Medical aspects of toxin weapons. Toxicology, 214: 210-220.
15. Boles, J.W., M.L. Pitt, R.D. LeClaire, P.H. Gibbsa and E. Torres et al., 2003. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin. Immunol., 108: 51-59.
16. Borio L., T. Inglesby, C.J. Peters, A.L. Schmaijohn and J.M. Hughes et al., 2002. Medical and public health management: Hemorrhagic fever viruses as biological weapons. JAMA, 287: 2391-2405.
17. Borzenkov, V.M., A.P. Pomerantsev and I.P. Ashmarin, 1993. The additive synthesis of a regulatory peptide in vivo: The administration of a vaccinal Francisella tularensis strain that produces beta-endorphin. Biull. Eksp. Biol. Med., 116: 151-153.
18. Bossi, P., A. Tegnell, A. Baka, F. Van Loock and J. Hendriks et al., 2004. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro. Surveill, 9: E15-16.
19. Bowen, J.E. and C.P. Quinn, 1999. The native virulence plasmid combination affects the segregational stability of a theta-replicating shuttle vector in Bacillus anthracis var. New Hampshire. J. Applied Microbiol., 87: 270-278.
20. Boyce, T.G., D.L. Swerdlow and P.M. Griffin, 1995. Escherichia coli 0157: H7 and the hemolytic-uremic syndrome. N. Engl. J. Med., 333: 364-368.
21. Bozheyeva, G., Y. Kunakbayev and D. Yeleukenov, 1999. Former Soviet Biological Weap-ons Facilities in Kazakhstan: Past, Present and Future. Center for Nonproliferation Stud-ies, Monterey Institute of International Studies, Monterey, California, pp: 1-20.
22. Bratu, S. and L.I. Lutwick, 2002. Active immunisation against human tickborne diseases. Expert Op in. Biol. Ther., 2: 187-195.
23. Breman, J.G. and D.A. Henderson, 2002. Diagnosis and management of smallpox. N. Engl. J. Med., 17: 1300-1308.
24. Broekhuijsen, M, P. Larsson, A. Johansson, M. Bystrom and U. Eriksson et al., 2003. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive ge-netic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J. Clin. Microbiol., 41: 2924-2931.
25. Bronze, M.S., M. M.Huycke, L.J. Machado, G.W. Voskuhl and R.A. Greenfield, 2002. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci., 323: 316-325.
26. Broussard, L.A., 2001. Biological agents: Weapons of warfare and bioterrorism. Mol. Diagn, 6: 323-333.
27. Bryden, J., 1989. Deadly Allies: Canadas Secret War, 1937-1947. McClelland and Stewart, Toronto, Ontario.
28. Butler, T., 2008. Yersinia Pestis. In: Antimicrobial Therapies and Vaccines Microbes. Yu, V.L. and D. Raoult (Eds.). Vol. 1. ESun Technologies Co. Ltd., Bittsburgh, PA.
29. Butt, A.A., K.E. Aldridge and C.V. Sanders, 2004. Infections related to the ingestion of sea-food Part I: Viral andbacterial infections. Lancet Infect. Dis., 4: 201-212.
30. Butzler, J.P., 2004. Campylobacter, from obscurity to celebrity. Clin. Microbiol. Infect., 10: 868-876.
31. Calisher, C.H., 1994. Medically important arboviruses of the United States and Canada. Clin. Microbiol. Rev., 7: 89-116.
32. Canter, D.A., D. Gunning, P. Rodgers L. O'connor, C. Traunero and C.J. Kempter, 2005. Remediation of B. anthracis contamination in the U.S. Department of Justice mail facility. Biosecur. Bioterror., 3: 119-127.
33. Carl, M., C.W. Tibbs, M.E. Dobson, S. Paparello and G.A. Dasch, 1990. Diagnosis of acute typhus infec-tion using the polymerase chain reaction. J. Infect. Dis., 161: 791-793.
34. Carman, J.A., P. Hamblelon and J. Melling, 1985. Bacillus anthracis, in Isolation and Identification of Micro-Organisms of Medical and Veterinary Importance. In: Society of Applied Bacteriology Technical Series 21, Collins, C.H.G. and M. Grange (Eds.). Academic Press, London, pp:207-214.
35. Casadevall, A., 2002. Passive antibody administration (immediate immunity) as a specific defense against biological weapons, Emerg. Infect. Dis., 8: 833-841.
36. Casadevall, A. and L. Pirofski, 2003. Exploiting the redundancy in the immune system: Vac-cines can mediate protection by eliciting unnatural immunity. J. Exp. Med., 197: 1401-1404.
37. Casadevall, A. and L. A. Pirofski, 2004. The weapon potential of a microbe. Trends Microbiol., 12: 259-263.
38. Celebi, G., F. Baruonu, F. Ayoglu, F. Cinar, A. Karadenizli, M.B. Ugur and S. Gedikoglu, 2006. Tularemia, a reemerging disease in northwest Turkey: Epidemiological investigation and evaluation of treatment responses. Japan J. Infect. Dis., 59: 229-234.
39. Center of Disease Control and Prevention, 1982. Blague Vaccine. MMWR, 22: 301-304.
40. Centers for Disease Control and Prevention, 1999. Update: Outbreak of Nipah virus, Malyasia and Singapore, 1999. MMWR, 48: 335-337.
41. Centers for Disease Control and Prevention, 2000. Lab oratory-acquired human glanders Maryland, May 2000. MMWR, 49: 532-535.
42. Center of Disease Control and Prevention, 2002a. Use of anthrax vaccine in response to ter-rorism: Supplemental recommendations of the Advisory Committee on Immunization Practices(ACIP). JAMA, 288: 2681-2682.
43. Center of Disease Control and Prevention, 2002b. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Bractices (ACIP). MMWR, 51: 1-10.
44. Center of Disease Control and Prevention, 2004. Chemical Emergencies, Facts About Ricin. CDC, Atlanta, GA.
45. Centers for Disease Control and Prevention, 2006. Human plague-four states, 2006. MMWR, 55: 940-943.
46. Centre of Disease Control and Prevetion, 2010. Surveillance for human west nile virus dis-ease-United States, 1999-2008. MMWR, 59: 1-17.
47. Chanteau, S, L. Rabarijaona, T. O'Brien, L. Rahalison and J. Hager et al., 1998. F1 antigenaemia in bubonic plague patients, a marker of gravity and efficacy of therapy. Trans. R. Soc. Trop. Med. Hyg., 92: 572-573.
48. Chanteau, S., M. Ratsitorahina, L. Rahalison, B. Rasoamanana and F. Chan et al., 2000. Current epidemiology of human plague in Madagascar. Microbes Infect., 2: 25-31.
49. Choi, E., 2002. Tularemia and Q fever. Med. Clin. North Am., 86: 393-416.
50. Christopher, G.W., M.B. Agan, T.J. Cieslak and P.E. Olson, 2005. History of US military contributions to the study of bacterial zoonoses. Military Med., 170: 39-48.
51. Christopher, G.W., T.J. Cieslak, J.A. Pavlin and Jr. E.M. Eitzen, 1997. Biological warfare: A his-torical perspective. J. Am. Med. Assoc., 278: 412-417.
52. Chua, K.B, S.K. Lam, K.J. Goh, P.S. Hooi and T.G. Ksiazek et al., 2001. The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malay-sia. J. Infect., 42: 40-43.
53. Cieslak, T.J., G.W. Christopher, M.G. Kortepeter, J.R. Rowe, J.A. Pavlin, R.C. Culpepper and Jr. E.M. Eitzen, 2000. Immunization against potential biological warfare agents. Clin. Infect. Dis., 30: 843-850.
54. Cohen, R.J. and J.L. Stockard, 1967. Pneumonic plague in an untreated plague-vaccinated individual. JAMA, 4: 365-366.
55. Cohen, R.J. and E. Marshall, 2001. BIOTERRORISM: Vaccines for biodefense: A system in distress. Science, 294: 498-501.
56. Coker, C., M. Majid and S. Radulovic, 2003. Development of Rickettsia prowazekii DNAvac-cine: Cloning strategies. Ann. N. Y. Acad. Sci., 990: 757-764.
57. Crook, L.D. and B. Tempest, 1992. Plague: A clinical review of 27 cases. Arch. Intern. Med., 152: 1253-1256.
58. Cuthbert, J.A., 2001. Hepatitis A: Old and new. Clin. Microbiol. Rev., 14: 38-58.
59. DaSilva, E.J., 1999. Biological warfare, bioterrorism, bidefence and the biological and toxin weapons conention. Elect. J. Biotechnol., 2: 99-120.
60. Daniels, P., T. Ksiazek and B.T. Eaton, 2001. Laboratory diagnosis of Nipah and Hendra vi-rus infections. Microbes Infect., 3: 289-295.
61. De Paepe, P., F. Gijsenbergh, F. Martens, Piette and W. Buylaert, 2005. Two fatal intoxications following ricin injection. Br. J. Clin. Pharmacol., 59: 125-126.
62. Dembek, Z., L.A. Smith and J.M. Rusnak, 2007. Botulinum toxin. J. Dis. Med. Pub. Health Prep., 1: 1-13.
63. Dennis, D.T., T.V. Inglesby and D.A. Henderson, J.G. Bartlett and M.S. Ascher et al., 2001. Tularemia as a biological weapon: Medical and public health management. JAMA, 285: 2763-2773.
64. Derbes, V.J., 1966. De mussis and the great plaque of 1348: A forgotten episode in bacterio-logical war. J. Am. Med. Assoc., 196: 59-62.
65. Dixon, T.C., M. Meselson, J. Guillemin and P.C. Hanna, 1999. Anthrax. N. Engl. J. Med., 341: 815-826.
66. Dorofe'ev, K.A., 1947. Classification of the causative agent of tularemia. Symp. Res. Works Inst. Epidemiol. Microbiol., 1: 170-180.
67. Duma, R.J., D.E. Sonenshine, F.M. Bozeman, J.M. Veazey and Jr. B.L. Elisberg et al., 1981. Epidemic typhus in the United States associated with flying squirrels. JAMA, 245: 2318-2323.
68. Eitzen, E.M. and E.T. Takafuji, 1997. Historical Overview of Biological Warfare. In: Medical Aspects of Chemical and Biological Warfare, Sidel, F.R., E.T. Takafujii and D.F. Franz (Eds.). Borden Institute, Washington, DC., pp: 415-423.
69. Elad, D., 2005. Risk assessment of malicious biocontamination of food. J. Food Brot., 68: 1302-1305.
70. Eleopra, R., V. Tugnoli, R. Quatrale, O. Rossetto and C. Montecucco, 2002. Botulinum Neu-Rtoxin Serotypes C and E: Clinical Tials. In: Scientific and Therapeutic Aspects of Botulinum Toxin 42, Brin, M.E., M. Hallett and J. Jankovic (Eds.). Lippincott Williams and Wilkins, New York, pp:441-450.
71. Ellis, J., P.C. Oyston, M. Green and R.W. Titball, 2002. Tularemia. Clin. Microbiol. Rev., 15: 631-646.
72. Elvin, S. J., A.M. Bennett and R.J. Bhillpotts, 2002. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol., 67: 384-393.
73. Emanuel, P.A., J. Dang, J.S. Gebhardt, J. Aldrich and E.A.E. Garber et al., 2000. Recombinant antibodies: A new reagent for biological agent detection. Biosens. Bioelectron., 14: 761-770.
74. Enderlin, G.L., Morales, R.F. Jacobs and J.T. Cross, 1994. Streptomycin and alternative agents for the treatment of tularaemia: Review of literature. Clin. Infect. Dis., 19: 42-47.
75. Fedorova, V.A., A.V. Betrova and Z.L. Devdariani, 2005. Influence of cultivation conditions on the expression of Yersinia pestis YopE. Zh. Mikrobiol. Epidemiol. Imunobiol., 4: 3-7.
76. Fenn, E.A., 2000. Biological warfare in eighteenth-century North America: Beyond jeffery amherst. J. Am. Hist., 86: 1552-1580.
77. Fenner, F., D. Henderson, I. Arita, Z. Jezek and I.D. Ladnyi, 1988. Smallpox and its Eradication. WHO, Geneva, Switzerland, pp: 1-68.
78. Fenollar, F., P.E. Fournier, M.B. Carrieri, G. Habib, T. Messana and D. Raoult et al., 2001. Risks factors and prevention of Q fever endocarditis. Clin. Infect. Dis., 33: 312-316.
79. Fine, D.L., B.A. Roberts, M.L. Teehee, S.J. Terpening and C.L. Kelly et al., 2007. Venezuelan equine encephalitis virus vac-cine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine, 25: 1868-1876.
80. Finnie, J.W., 2003. Pathogenesis of brain damage produced in sheep by Clostridium perfrin-gens type D epsilon toxin: A review. Aust. Vet. J., 81: 219-221.
81. Fisher-Hoch, S.P., L. Hutwanger, B. Brown and J.B. McCormick, 2000. Effective vaccine's for Lass a fever. J. Virol., 74: 6777-6783.
82. Foran, P., N. Mohammed, G. Lisk, S. Nagwaney and G.W. Lawrence et al., 2003. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared to the long-lasting type A: Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem., 278: 363-1371.
83. Franz, D.R. and N.K. Jaax, 1997. Ricin Toxin. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Zajtchuk, R. and R.F. Bellamy (Eds.). TMM Bublications, Washington, DC., pp: 631-42.
84. Franz, D.R., P.B. Jahrling, A.M. Friedlander, D.J. McClain and D.L. Hoover et al., 1997. Clinical recognition and man-agement of patients exposed to biological warfare agents. JAMA, 278: 399-411.
85. Garrett, L., 2000. Betrayal of Trust: The Collapse of Global Bublic Health. Hyperion Publisher Inc., New York, USA.
86. Ghabriel, M.N., C. Zhu, B.L. Reilly, B.C. Blumbergs, J. Manavis and J.W. Fmme, 2000. Toxin-induced vasogenic cerebral oe-dema in a rat model. Acta Neurochir. Suppl., 76: 231-236.
87. Glynn, J.R, R.B. Hornick, M.M. Levine and D.J. Bradley, 1995. Infecting dose and severity of ty-phoid: analysis of volunteer data and examination of the influence of the definition of ill-ness used. Epidemiol. Infect, 115: 23-30.
88. Glynn, M.K. and T.V. Lynn, 2008. Brucellosis. J. Am. Yet. Med. Assoc., 233: 900-908.
89. Gorvel, J.P. and E. Moreno, 2002. Brucella intracellular life: From invasion to intracellular replication. Yet. Microbiol., 90: 281-297.
90. Gregory, D.W. and W. Schaffner, 1997. Psittacosis. Semin. Respir. Infect., 12: 7-11.
91. Grunow, R, W. Splettstoesser, S. Mcdonald, C. Otterbein and T. O'Brien et al., 2000. Detection of Francisella tu-larensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR. Clin. Diagn. Lab. Immunol., 7: 86-90.
92. Guarner, J. and S.R. Zaki, 2006. Histopathology and Immunohistochemistry in the Diagnosis of Bioterrorism Agents. J. Histochem. Cytochem., 54: 3-11.
93. Guillemin, J, 1999. Anthrax: The Investigation of a Deadly Outbreak. University of California Press, Berkley, California.
94. Gurycova, D., 1998. First isolation of Francisella tularensis subsp. tularensis in Europe. Eur. J. Epidemiol., 14: 797-802.
95. Hallin, G.W., S.Q. Simpson, R.E. Crowell, D.S. James, F.T. Koster, G.J. Mertz and H. Levy, 1996. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit. Care Med., 24: 252-258.
96. Hanna, P, 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol., 225: 13-35.
97. Hart, M.K., K. Caswell-Stephan, R. Bakken, R. Tammariello and W. Pratt et al., 2000. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine., 18: 3067-3075.
98. Hatheway, C.L., 1992. Clostridium Botulinum and other Clostridia that Produce Botulinum Neurotoxins. In: Clostridium Botulinum: Ecology and Control in Foods, Hauschild, A.H.W. and K.L. Dodds (Eds.). Marcel Dekker Inc., New York, pp: 3-10.
99. Henderson, D.A., T.V. Inglesby, J.G. Bartlett, M.S. Ascher and E. Eitzen et al., 1999. Smallpox as a biological weapon: Medical and public health management. Working group on civilian biodefense. JAMA, 281: 2127-2137.
100. Higgins, J.A., M. Cooper, L. Schroeder-Trucker, S. Black and D. Miller et al., 2002. A field investigation of Ba-cillus anthracis contamination of U.S. Department of Agriculture and other Washington, D.C., buildings during the anthrax attack of October 2001. Applied Environ. Microbiol., 69: 593-599.
101. Hilleman, M.R., 2002. Overview: Cause and prevention in biowarfare and bioterrorism. Vaccine, 20: 3055-3067.
102. Holen, O., 2010. Vaccine against dengue fever under development. Tidsskr Nor. Laegeforen, 130: 256-256.
103. Hollis, D.G., R.E. Weaver, A.G. Steigerwalt, J.D. Wenger, C.W. Moss and D.J. Brenner, 1989. Francisella philomiragia comb.nov. (formerly Yersinia philomiragia) and Francisella tularensis biogroup novicida (formerly Francisella novicida) associated with human disease. J. Clin. Microbiol., 27: 1601-1608.
104. Holty, J.E., D.M. Bravata, H. Liu, R.A. Olshen, KM. McDonald and D.K Owens, 2006. Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann. Internal Med., 144: 270-280.
105. Holzer, V.E., 1962. Botulism from inhalation. Med. Klin, 57: 1735-1738.
106. Hornick, R.B. and H.T. Eigelsbach, 1966. Eigelsbach, Aerogenic immunization of man with live Tulare-mia vaccine. Bacteriol. Rev., 30: 532-538.
107. Hottle, G.A., C. Nigg and J.A. Lichty, 1947. Studies on botulinum toxoids, types A and B. II. Methods for determining antigenicity in animals. J. Immunol., 55: 255-262.
108. Hubalek, Z., W. Sixl and J. Halouzka, 1998. Francisella tularensis in Dermacentor reticula-tus ticks from the Czech Republic and Austria. Wien. Klin. Wochenschr., 110: 909-910.
109. Inglesby, T.Y., D.T. Dennis, D.A. Henderson, J.G. Bartlett and M.S. Ascher et al., 2000. Blagueas a biological weapon: Medical and public health management. Working group on civilian biodefense. JAMA, 283: 2281-2290.
110. Inglesby, T.Y., T. O'Toole, D.A. Henderson, J.G. Bartlett and M.S. Ascher et al., 2002. Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA, 287: 2236-2252.
111. Jackson, B.J., M.E. Hugh-Jones, D.M. Adair, G. Green and K.K. Hill et al., 1998. BCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: The presence of multiple Bacillus anthracis strains in different victims. Broc. Natl. Acad. Sci., 95: 1224-1229.
112. Jiang, J., J.J.Temenak, A.L. Richards, 2003. Real-time BCR duplex assay for Rickettsia prowazekii and Borrelia recurrentis. Ann. N. Y. Acad. Sci., 990: 302-310.
113. Johnson, E., N. Jaax, J. White, B. Jahrling, 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Bathol., 76: 227-236.
114. Josefson, D., 2001. US fear of bioterrorism spreads as anthrax cases increase. Br. Med. J., 323: 877-878.
115. Kagawa, F.T., J.H. Wehner and V. Mohindra, 2003. Q fever as a biological weapon. Semin. Respir. Infect., 18: 183-195.
116. Kaper, J.B., J.G. Moms and M.M. Levine, 1995. Cholera. Clin. Microbiol. Rev., 8: 316-316.
117. Keim B., A. Kalif, J. Schupp, K. Hill and S.E. Travis et al., 1997. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J. Bacteriol, 179: 818-824.
118. Kelly, D.J., A.L. Richards, J. Temenak, D. Strickman and G.A. Dasch, 2002. The past and present threat of rickettsial diseases to military medicine and international public health. Clin. Infect. Dis., 34: S145-169.
119. Kenyon, R.H, Jr. K.T. McKee, B.M. Zack, M.K. Rippy and A.B. Vogel et al., 1992. Aerosol infection of rhesus ma-caques with Junin virus. Inter. Virol, 33: 23-31.
120. Kiel, J.L, J.E. Barker, E.A. Holwitt, R.B. McCreary and C.J. Andrews et al., 2008. Geographical distribution of genotypic and phenotypic markers among Bacillus anthracis isolates and related species by his-torical movement and horizontal transfer. Folia. Microbiol, 53: 472-478.
121. Kilonzo, B.S, T.J. Mbise, D.C. Mwalimu and L. Kindamba, 2006. Observations on the en-demicity of plague in Karatu and Ngorongoro, northern Tanzania. Tanzania Health Res. Bull, 8: 1-6.
122. Knisely, R.F, 1966. Selective medium for Bacillus anthracis. J. Bacteriol, 92: 784-786.
123. Kolavic, S.A, A. Kimura, S.L. Simons, L. Slutsker, S. Barth and C.E. Haley, 1997. An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. JAMA, 278: 396-398.
124. Kornpeter, M.G, T.J. Cieslak and E.M. Eitzen, 2001. Bioterrorism. J. Environ. Health, 63: 21-24.
125. Krakauer, T, 2005. Chemotherapeutics targeting immune activation by staphylococcal su-perantigens. Med. Sci. Monit, 11: RA29O-295.
126. Kukreja, R. and B.R. Singh, 2009. Botulinum Neurotoxins: Structure and Mechanism of Action: Microbial Toxins: Current Research and Future Trends. Caister Academic Press, New York.
127. La Scola, B. and D. Raoult, 1997. Laboratory diagnosis of rickettsioses: Current approaches to diagnosis of old and new rickettsial diseases. J. Clin. Microbiol, 35: 2715-2727.
128. LaForce, F.M, 1994. Anthrax. Clin. Infect. Dis, 19: 1009-1014.
129. Lamb, A, 2001. Biological weapons: The facts not the fiction. Clin. Med, 1: 502-504.
130. Lane, H.C, J. La Montagne and A.S. Fauci, 2001. Bioterrorism: A clear and present danger. Nat. Med, 7: 1271-1273.
131. Lee, P.W., H.L. Amyx, R. Yanagihara, D.C. Gajdusek, D. Goldgaber and Jr. C.J. Gibbs, 1985. Partial characterization of Prospect Hill virus isolated frommeadowvoles in the United States. J. Infect. Dis, 152: 826-829.
132. Lee, M.D. and R.Y. Wang, 2005. Toxalbumins. In: Critical Care Toxicology, Brent, J, K.L. Wallace, K.H. Burkhart, S.D. Phillips and J.W. Donovan (Eds.). Elsevier Mosby, Philadelphia (PA), pp:1345-1349.
133. Lee, J.S, A.G. Hadjipanayis and M.D. Parker, 2005. Viral vectors for use in the development of biodefense vaccines. Adv. Drug Deliv. Rev, 57: 1293-1314.
134. Leitenberg, M, 2001. Biological weapons in twentieth century: A review and analysis. Crit. Rev. Microbiol, 27: 267-320.
135. Leppla, S.H, 1991. The Anthrax Toxin Complex. In: Source Book of Bacterial Protein Toxins, Alouf, J. and J.H. Freer (Eds.). Academic Press, London, pp: 277-302.
136. Ligon, B.L, 2006. Plague: A review of its history and potential as a biological weapon. Semin. Pediatr. Infect. Dis, 17: 161-170.
137. Lord, J.M, L.M. Roberts, J.D. Robertus, 1994. Ricin: Structure, mode of action, and some current applications. FASEB J, 8: 201-208.
138. Lub, M, A.N. Sergeev, O.V. P'Iankov, O.G. P'iankova, V.A. Petrishchenko and L.A. Kotliarov, 1995. Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route. Vopr. Virusol, 40: 158-161.
139. Lucas, M.E, J.L. Deen, L. Von Seidlein, X.Y. Wang and J. Ampuero et al. 2005. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med, 352: 757-767.
140. Mac Kenzie, W.R., N.J. Hoxie, M.E. Proctor, M.S. Gradus and K.A. Blair et al., 1994. A massive outbreak in Milwau-kee of Cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med, 331: 161-167.
141. Mackinnon, P.J. and M.R. Alderton, 2000. n investigation of the degradation of the plant toxin, ricin, by sodium hypochlorite. Toxicon, 38: 287-291.
142. Manchee, R.J, M.G. Brosler, A.J. Stagg and S.E. Hibbs, 1994. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish Island of Gruinard. Applied Environ. Microbiol, 60: 4167-4171.
143. Mantis, N.J, 2005. Vaccines against the category B toxins: staphylococcal enterotoxin B, epsilon toxin and ricin. Adv. Drug Deliv. Rev, 57: 1424-1439.
144. Marmion, B.P, R.A. Ormsbee, M. Kyrkou, J. Wright and D.A. Worswick et al., 1984. Vaccine prophylaxis of abattoir-associated Q fever. Lancet, 2: 1411-1414.
145. Marrie, T.J. and D. Raoult. 2002. Update on Q fever, including Q fever endocarditis. Curr. Clin. Top. Infect. Dis 22: 97-124.
146. Mattix, M.E, R.E. Hunt, C.L. Wilhelmsen and A.J. Johnson and W.B. Baze, 1995. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatto). Toxicol. Pathol, 23: 262-268.
147. Maurm, M. and D. Raoult, 1999. Q fever. Clin. Microbiol. Rev, 12: 518-553.
148. Mayor, A, 1997. Dirty tricks in ancient warfare. Mil. Hist. Q, 10: 32-37.
149. Mayor, A, 2003. Greek Fire, Poison Arrows and Scorpion Bombs: Biological and Chemical Warfare in the Ancient World. Overlook Duckworth, Woodstock, New York.
150. McCoy, G.W. and C.W. Chapin, 1912. Further observations on a plaque-like disease of rodents with a preliminary note on the causative agent, Bacterium tularense. J. Infect. Dis., 10: 61-72.
151. McGovern, T.W. and A.M. Friedlander, 1997. Blague. In: Medical Aspects of Chemical and Biological Warfare, Sidell, F.R, E.T. Takafuji and D.R. Franz (Eds.). Walter Reed Army Medical Center, Borden Institute, Washington DC.
152. Memish, Z.A. and H.H. Balkhy, 2004. Brucellosis and international travel. J. Travel. Med., 11: 49-55.
153. Middlebrook, J.L. and D.R. Franz, 1997. Botulinum Toxins. In: Textbook of Military Medicine. Part I. Warfare, Weaponry and then Casualty: Medical Aspects of Chemical and Biological Warfare 33, Slidell, F.R, E.T. Takafuji and D.R. Franz (Eds.). Borden Institute, Walter Reed Army Medical Center, Washington, DC, pp: 643-654.
154. Miller, J, S. Engelberg and W.J. Broad, 2002. Germs: Biological Weapons and America's Secret War. GK Hall, Waterville, Me.
155. Mobley, J.A, 1995. Biological warfare in the twentieth century: lessons from the past, challenges for the future. Mil. Med, 160: 547-553.
156. Monath, T.P., 2001. Yellow fever: An update. Lancet Infect. Dis., 1: 11-20.
157. Montoya, J.G. and O. Liesenfeld, 2004. Toxoplasmosis. Lancet, 363: 1965-1976.
158. Moran, G.J, D.A. Talan and F.M. Abrahamian, 2008. Biological terrorism: Review. Infect. Dis. Clm. North. Am, 22: 145-187.
159. Musher, D.M. and B.L. Musher, 2004. Contagious acute gastrointestinal infections. N. Engl. J. Med, 351: 2417-2427.
160. Nachamkin, I, A.B. Mishu and T. Ho, 1998. Campylobacter species and Guillain-Barre syndrome. Clm. Microbiol. Rev, 11: 555-567.
161. Nagahama, M. and J. Sakurai, 1992. High-affinity binding of Clostridium perfringens epsilon-toxin to rat brain. Infect. Immun, 60: 1237-1240.
162. Nagahama, M, S. Ochi and J. Sakurai, 1998. Assembly of Clostridium perfringens epsilon-toxin on MDCK cell membrane. J. Nat. Toxins, 7: 291-302.
163. Nass, M, 1991. The labyrinth of biological defense. PSR Quart, 1: 24-30.
164. Nathan, N, M. Barry, M. van Herp and H. Zeller, 2003. Shortage of vaccines during a yellow fever outbreak in Guinea. Lancet, 358: 2129-2130.
165. Navarro, E, M.A. Casao and J. Solera, 2004. Diagnosis of human brucellosis using PCR. Exp. Rev. Mol. Diagn, 40: 115-123.
166. Nichol, S.T, C.F. Spiropoulou, S. Morzunov, F.E. Rollin and T.G. Ksiazek, 1993. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science, 262: 914-917.
167. Nicoletti, P, 1989. Immune Responses and Vaccination. In: Brucellosis, Madkour, M.M. (Ed.). Butterworths, London, pp: 263-269.
168. Niyogi, S.K, 2005. Shigellosis. J. Microbiol, 43: 133-143.
169. Noah, D.L, K.D. Huebner, R.G. Darling and J.F. Waeckerle, 2002. The history and threat of biological warfare and terrorism. Emerg. Med. Clin. North. Am, 20: 255-271.
170. Nurgaleeva, R.G, E.A. Tkachenko, A.G. Stepanenko, I.M. Mustafin and and S.G. Kireev et al., 1999. An epidemiological analysis of hemorrhagic fever with renal syndrome morbidity in the republic of Bashkortostan in 1997. Zh. Mikrobiol. Epidemiol. Immunobiol, 6: 45-49.
171. Olsufjev, N.G, O.S. Emelyanova and T.N. Dunaeva, 1959. Comparative study of strains of B. tularense in the old and new world and their taxonomy. J. Hyg. Epidemiol. Microbiol. Immunol, 3: 138-149.
172. Oyston, P.C, D.W. Payne, H.L. Havard, E.D. Williamson and R.W. Titball, 1998. Production of a non-toxic site-directed mutant of Clostridium perfringens epsilon-toxin which induces protective immunity in mice. Microbiology, 144: 333-341.
173. Ozcurumez, M.P, N. Kischel, H. Priebe, W. Splettstösser, E.J. Finke and R. Grunow, 2004. Comparison of enzyme-linked immunosorbent assay, Western blotting, micro agglutination, indirect immunofluorescence assay and flow cytometry for serological diagnosis of tularemia. Clm. Diagn. Lab. Immunol, 11: 1008-1015.
174. O'Brien, J, A. Friedlander, T. Drier, J. Ezzell and S. Leppla, 1985. Effects of anthrax toxin compounds on human neutrophils. Infect. Immun, 47: 306-310.
175. Pappas, G, N. Akritidis and E.V. Tsianos, 2005a. Attack scenarios with rickettsial species: Implications for response and management. Ann. N. Y. Acad. Sci, 163: 451-458.
176. Pappas, G, N. Akritidis, M. Bosilkovski and E. Tsianos, 2005b. Brucellosis. N. Engl. J. Med, 352: 2325-2336.
177. Pappas, G, P. Papadimitriou, N. Akritidis, L. Christou and E.V. Tsianos, 2006. The new global map of human brucellosis. Lancet. Infect. Dis, 6: 91-99.
178. Parent, M.A, K.N. Berggren, LW. Kummer, L.B. Wilhelm, F.M. Szaba, I.K. Mullarky and S.T. Smiley, 2005. Cell mediated protection against pulmonary Yersiniapestis infection. Infect. Immun, 73: 7304-7310.
179. Parry, C.M, T.T. Hien, G. Dougan, N.J. White and J.J. Farrar, 2002. Typhoid fever. N. Engl. J. Med, 347: 1770-1782.
180. Perine, P.L, B.P. Chandler, D.K. Krause, P. McCardle and S. Awoke et al., 1992. A clinico-epidemiological study of epidemic typhus in Africa. Clin. Infect. Dis, 14: 1149-1158.
181. Perry, R.D. and J.D. Fetherston, 1997. Yersinia pestis: Etiologic agent of plague. Clin. Microbiol. Rev, 10: 35-66.
182. Pezard, C, E. Duflot and M. Mock, 1993. Constructing of Bacillus anthracis mutant strains producing a single toxin component. J. Gen. Microbiol, 139: 2459-2463.
183. Philipotts, R.J, L.D. Jones and S.C. Howard, 2002. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine, 20: 1497-1504.
184. Phillpotts, R.J, T.L. Lescott and S.C. Jacobs, 2000. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV. Acta. Virol, 44: 233-239.
185. Pile, J.C, J.D. Malone, E.M. Eitzen and A. Friedlander, 1998. Anthrax as a potential biological warfare agent. Arch. Intern. Med, 158: 429-434.
186. Plourde, P.J, J. Embree, F. Friesen and G. Lindsay, 1992. Glandular tularemia with typhoidal features in a Manitoba child. Can. Med. Assoc. J, 146: 1953-1955.+
187. Pohanka, M. and B. Skladal, 2009. Bacillus anthracis, Francisella tularensis and Y. pestis. The most important bacterial warfare agents. Rev. Folia Microbiol, 54: 263-272.
188. Pomerantsev, A.F. and N.A. Staritsyn, 1996. Behaviour of heterologous recombinant plasmid pCET in cells of Bacillus anthracis. Genetika, 32: 500-509.
189. Pomerantsev, A.B, N.A. Staritsin, Y.V. Mockov and L.I. Marinin, 1997. Expression of cereolysine ab genes in Bacillus anthracis vaccine strain ensures protection against experimental haemolytic anthrax infection. Vaccine, 15: 1846-1850.
190. Prior, R.G, L. Klasson, B. Larsson, K. Williams and L. Lindler et al., 2001. Preliminary analysis and annotation of the partial genome sequence of Francisella tularensis strain Schu 4. J. Applied Microbiol, 91: 571-623.
191. Pullen, R.L. and B.M. Stuart, 1945. Tularemia: Analysis of 225 cases. JAMA, 129: 495-500.
192. Qadri, F, A.M. Svennerholm, A.S.G. Faruque and R.B. Sack, 2005. Enterotoxigenic Escherichia coli in developing countries: Epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev, 18: 465-483.
193. Queipo-Ortuno, M.I, J.D. Colmenero, G. Baeza and B. Morata, 2005. Comparison between LightCycler realtime polymerase chain reaction (PCR) assay with serum and PCR-enzyme- linked immunosorbent assay with whole blood samples for the diagnosis of human brucellosis. Clm. Infect. Dis., 40: 260-264.
194. Rahalison, L, E. Vololonirina, M. Ratsitorahina and S. Chanteau, 2000. Diagnosis of bubonic plague by BCR in Madagascar under field conditions. J. Clin. Microbiol, 38: 260-263.
195. Ramirez, A, 1996. Was The Blague of Athens Really Ebola. New York Times, New York.
196. Raoult, D, J.B. Ndihokubwayo, H. Tissot-Dupont, V. Roux, B. Faugere, R. Abegbinni and R.J. Birtles, 1998. Outbreak of epidemic typhus associated with trench fever in Burundi. Lancet, 352: 353-358.
197. Raoult, D, T. Marrie and J. Mege, 2005. Natural history and pathophysiology of Q fever. Lancet Infect. Dis., 5: 219-226.
198. Ray, S.M, S.D. Ahuja, B.A. Blake, M.M. Farley and M. Samuel et al., 2004. Population-based surveillance for Yersinia enterocolitica infections in Food Net sites, 1996-1999: Higher risk of disease in infants and minority populations. Clin. Infect. Dis., 38: S181-189.
199. Riedels, S, 2005. Blague: From natural disease to bioterrorism. Broc. Bayl. Univ. Med. Center, 18: 116-124.
200. Robertson, D.L. and S.H. Leppla, 1986. Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. Genetic, 44: 71-78.
201. Roffey, R, A. Tegnell and F. Elgh, 2002. Biological warfare in a historical perspective. Clin. Microbiol. Infect, 8: 450-454.
202. Roux, J, 1989. Brucella Vaccines in Humans. In: Brucellosis, Butterworths, Madkour, M.M. (Ed.). London, pp: 244-249.
203. Rusnak, J.M, M. Kortepeter, R. Ulrich, M. Boh and E. Boudreau, 2004. Laboratory exposures to staphylococcal enterotoxin B. Emerg. Infect. Dis., 10: 1544-1549.
204. Russell, J.C, 1968. That earlier plague. Demography, 5: 174-184.
205. Ryan, K.J. and C.S. Ray, 2004. Sherris Medical Microbiology. 4th Edn, McGraw Hill, New York, pp: 525-528.
206. Salsbery, C.E, 1926. Anthrax aggressin. J. Am. Vet. Med. Assoc, 68: 755-757.
207. Saslaw, S, H.T. Eigelsbach, J.A. Prior, J.E. Wilson and S. Carhardt, 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Inter. Med, 107: 702-714.
208. Schep, L.J, W.A, Temple, G.A. Butt and M.D. Beasley, 2009. Ricin as a weapon of mass terror: Separating fact from fiction. Environ. Int., 35: 1267-1271.
209. Schmaljohn, C, 2009. Vaccines for hantaviruses. Vaccine, 27: D6l-64.
210. Schmitt, P, W. Splettstosser, M.P. Ozcurumez, E.J. Finke and R. Grunow, 2005. A novel screening ELISA and a confirmatory Western blot useful for diagnosis and epidemiological studies of tularemia. Epidemiol. Infect, 133: 759-766.
211. Schoepp, R.J, J.F. Smith and M.D. Parker, 2002. Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology, 302: 299-309.
212. Scola, B.L, 2002. Current laboratory diagnosis of Q fever. Semin. Pediatr. Infect. Dis, 13: 257-262.
213. Sellek, R, O. Jimenez, C. Aizpurua, B. Fernandez-Frutos and P. De Leon et al., 2008. Recovery of Francisella tularensis from soil samples by filtration and detection by real-time PCR and ELISA. J. Environ. Momt, 10: 362-369.
214. Sjostedt, A, A. Tarnvik and G. Sandstrom, 1996. Francisella tularensis: Hostparasite inter-action. FEMS Immunol. Med. Microbiol, 13: 181-184.
215. Small, P.M. and P.I. Fujiwara, 2001. Management of tuberculosis in the United States. N. Engl. J. Med, 345: 189-210.
216. Smart, J.K, 1997. History of Chemical and Biological Warfare: An American Perspective. In: Medical Aspects of Chemical and Biological Warfare, Si dell, F.R, E.T. Takafuji and D.R. Franz (Eds.). Vol 3. OSG, Textbook of Military Medicine: Part I, Washington, DC, pp: 9-86.
217. Smith, H.V. and G.D. Corcoran, 2004. New drugs and treatment for cryptosporidiosis. Curr. Opin. Infect. Dis, 17: 557-564.
218. Smith, L.A, 2006. Bacterial Protein toxins as Biological Weapons. In: The Comprehensive Sourcebook of Bacterial Protein Toxins, Vol. 62. Alouf, J. and M.Popoff (Eds.). Academic Press, London, pp: 1019-1030.
219. Smither, S.J, J. Hill, B.L. Van Baar, A.G. Hulstb, A.L. de Jongb and R.W. Titball, 2007. Identification of outer membrane proteins of Yersinia pestis through biotinylation. J. Microbiol. Meth., 68: 26-31.
220. Spink, W.W, J.W. Hall, J. Finstad and E. Mallet, 1962. Immunization with viable Brucella organisms results of a safety test in humans. Bull. World Health Organ, 26: 409-419.
221. Stephenson, E.H, E.W. Larson and J.W. Dominik, 1984. Effect of environmental factors on aerosol-induced Lass a virus infection. J. Med. Virol, 14: 295-303.
222. Stern, J, 1999. The Ultimate Terrorists. Harvard University Press, Cambridge.
223. Sterne, M, 1939. The immunization of laboratory animals against anthrax. J. S. Afr. Vet. Med. Assoc, 13: 53-57.
224. Stienlauf, S, A. Eisenkraft, E. Robenshtok and A. Hourvitz, 2002. Viral encephalitis caused by biowarfare agents. Harefuah, 141: 121-121.
225. Sullivan, N.J, T.W. Geisbert, J.B. Geisbert, L. Xu and Z.Y. Yang et al., 2003. Accelerated vaccination for Ebola virushaemorrhagic fever in non-human primates. Nature, 424: 681-684.
226. Tamilselvam, B. and S. Daefler, 2008. Francisella targets cholesterol-rich host cell membrane domains for entry into macrophages. J. Immunol, 180: 8262-8271.
227. Tanabe, M, H.S. Atkins, D.N. Harland, S.J. Elvin and A.J. Stagg et al., 2006. The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection. Infect. Immun, 74: 3687-3691.
228. Tims, T.B. and D.V. Lim, 2004. Rapid detection of Bacillus anthracis spores directly from powders with an evanescent wave fiber-optic biosensor. J. Microbiol. Meth, 59: 127-130.
229. Titball, R.W, P.C.B. Turnbull and R.A. Huston, 1991. The monitoring1 and detection of Bacillus anthracis in the environment. J. Applied Bacteriol. Symp, 20: 9-18.
230. Titball, R.W. and E.D. Williamson, 2001. Vaccination against bubonic and pneumonic plague. Vaccine, 19: 4175-4184.
231. Titball, R.W, J. Hill, D.G. Lawton and K.A. Brown, 2003. Yersinia pestis and plague. Biochem. Soc. Trans, 31: 104-107.
232. Toro, J, J.D. Vega, A.S. Khan, J.N. Mills and B. Badula et al., 1998. An outbreak of hantavirus pulmonary syndrome. Chile, 1997. Emerg. Infect. Dis., 4: 687-694.
233. Torok, T.J, R.V. Tauxe, R.B. Wise, J.R. Livengood and R. Sokolow et al., 1997. A large community outbreak of salmonellosiscaused by intentional contamination of restaurant salad bars. JAMA, 278: 389-395.
234. Tsai, T.F, 2000. Flaviviruses. In: Rrinciples and Bractice of Infectious Diseases, Mandell, G.L, J.E. Bennett and R. Dolin (Eds.). 5th Edn, Churchill Livingstone, Philadelphia, pp: 1714-1736.
235. Tucker, J.B, 1999. Historical trends related to bioterrorism: An empirical analysis. Emerg. Infect. Dis., 5: 498-504.
236. Turnbull, B.C.B, 1999. Definitive identification of Bacillus anthracis: A review. J. Applied Microbiol, 2: 237-240.
237. WHO, 1970. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of CONSultants. WHO, Geneva.
238. WHO, 2004. Human plague in 2002 and 2003. Wkly Epidemiol. Rec, 79: 301-306.
239. Waag, D.M, M.J. England and M.L. Bitt, 1997. Comparative efficacy of a Coxiella bur-netii chloroform: Methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. Vaccine, 15: 1779-1783.
240. Waag, D.M, M. J. England, C.R. Bolt and J.C. Williams, 2008. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular Immune responses to Coxiella burnetii. Clin. Vac. Immunol, 15: 1505-1512.
241. Wang, T, Z. Qi, B. Wu, Z. Zhu and Y. Yang et al., 2008. A new purification strategy for fraction 1 capsular antigen and its efficacy against Yersinia pestis virulent strain challenge. Brotein Expr. Burif, 61: 7-12.
242. Weber, D.J. and W.A. Rutala, 2001. Risks and prevention of transmission of rare zoonotic diseases. Clm. Infect. Dis., 32: 446-446.
243. Wein, L.M. and Y. Liu, 2005. Analyzing a bioterror attack on the food supply: The case of botulmum toxin in milk. Proc. Natl. Acad. Sci., 102: 9984-9999.
244. Wheelis, M., L. Rozsa and M. Dando, 2006. Deadly Cultures: Biological Weapons Since 1945. Harvard University Press, UK., pp: 284-293, 301-303.
245. Whitehouse, C.A. and H.E. Hottel, 2006. Comparison of five commercial DNA extraction kits for the recovery of Francisella tularensis DNA from spiked soil samples. Mol. Cell. Frobes, 21: 92-96.
246. Williams, P. and D. Wallace, 1989. Unit 731: Japan's Secret Biological Warfare in World War II. 2nd Edn., The Free Press, New York.
247. Young, E.J., 1995. An overview of human brucellosis. Clin. Infect. Dis., 21: 283-289. ass, M., 1991. The labyrinth of biological defense. PsI Q., 1: 24-24.